Adenosine A2A receptors and brain injury:: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation

被引:212
作者
Chen, Jiang-Fan
Sonsalla, Patricia K. [1 ]
Pedata, Felicita [2 ]
Melani, Alessia [2 ,6 ]
Domenici, Maria Rosaria [3 ]
Popoli, Patrizia [3 ]
Geiger, Jonathan [4 ]
Lopes, Luisa V. [5 ]
De Mendonca, Alexandre [5 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA
[2] Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy
[3] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy
[4] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA
[5] Univ Lisbon, Fac Med, Inst Mol Med, Inst Pharmacol & Neurosci,Dept Neurol, P-1649028 Lisbon, Portugal
[6] IRCCS, Ctr Neurol Bonino Pulejo, I-98124 Messina, Italy
关键词
adenosine receptor; adenosine A(2A) receptors; purinergic receptors; neuroprotection; stroke ischemia; Parkinson's disease; Huntington's disease; multiple sclerosis; HIV-1-associated dementia; caffeine;
D O I
10.1016/j.pneurobio.2007.09.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This review summarizes recent developments that have contributed to understand how adenosine receptors, particularly A(2A) receptors, modulate brain injury in various animal models of neurological disorders, including Parkinson's disease (PD), stroke, Huntington's disease (HD), multiple sclerosis, Alzheimer's disease (AD) and HIV-associated dementia. It is clear that extracellular adenosine acting at adenosine receptors influences the functional outcome in a broad spectrum of brain injuries, indicating that A(2A)Rs may modulate some general cellular processes to affect neuronal cells death. Pharmacological, neurochemical and molecular/genetic approaches to the complex actions of A(2A) receptors in different cellular elements suggest that A(2A) receptor activation can be detrimental or protective after brain insults, depending on the nature of brain injury and associated pathological conditions. An interesting concept that emerges from these studies is A(2A)R's ability to fine tune neuronal and glial functions to produce neuroprotective effects. While the data presented here clearly highlight the complexity of using adenosinergic agents therapeutically in PD and other neurodegenerative disorders and point out many areas for further inquiry, they also confirm that adenosine receptor ligands, particularly A(2A) receptor ligands, have many promising characteristics that encourage the pursuit of their therapeutic potential. (C) 2007 Published by Elsevier Ltd.
引用
收藏
页码:310 / 331
页数:22
相关论文
共 223 条
  • [21] Adenosine A(1) receptor agonists as clinically viable agents for treatment of ischemic brain disorders
    Bischofberger, N
    Jacobson, KA
    vonLubitz, DKJE
    [J]. NEUROPROTECTIVE AGENTS - THIRD INTERNATIONAL CONFERENCE, 1997, 825 : 23 - 29
  • [22] Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics
    Blum, D
    Hourez, R
    Galas, MC
    Popoli, P
    Schiffmann, SN
    [J]. LANCET NEUROLOGY, 2003, 2 (06) : 366 - 374
  • [23] Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists
    Bona, E
    Aden, U
    Gilland, E
    Fredholm, BB
    Hagberg, H
    [J]. NEUROPHARMACOLOGY, 1997, 36 (09) : 1327 - 1338
  • [24] BOUMA MG, 1994, J IMMUNOL, V153, P4159
  • [25] Bouma MG, 1997, J IMMUNOL, V158, P5400
  • [26] Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells
    Brodie, C
    Blumberg, PM
    Jacobson, KA
    [J]. FEBS LETTERS, 1998, 429 (02): : 139 - 142
  • [27] 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease
    Brouillet, E
    Jacquard, C
    Bizat, N
    Blum, D
    [J]. JOURNAL OF NEUROCHEMISTRY, 2005, 95 (06) : 1521 - 1540
  • [28] Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO
  • [29] 2-E
  • [30] Buscemi L., 2006, ADENOSINE RECEPTORS